The available evidence consists primarily of animal studies and limited early-phase human trials, with no published phase III clinical trial data demonstrating efficacy in inflammatory bowel disease (IBD).[1][2] The literature describes BPC-157 as a stable gastric pentadecapeptide that was tested in phase II clinical trials for inflammatory bowel disease (referenced as PL 14736), with reports indicating it was "safe" and had "no side effects." However, a 2025 review emphasizes that BPC-157 "has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans."[1][3][2] The preclinical evidence is extensive but limited to animal models
It is rare, but the immune-modulatory effects of weight loss and hormonal changes could theoretically trigger autoimmune responses in susceptible individuals
You can check the Mounjaro savings card, Ozempic savings card, Wegovy savings card, and Zepbound savings card or consider using the self-pay option provided by LillyDirect (Eli Lilly) or NovoCare Pharmacy (Novo Nordisk)
Provides whole-body antioxidant support in both fat and water-soluble environments*
albicans , C
Quantitative transcriptome, proteome, and sulfur metabolite profiling of the Saccharomyces cerevisiae response to arsenite